Fiche centre
Research Site
Edinburgh — United Kingdom
Essais liés3clinical trials
VilleEdinburghlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06455449
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Anifrolumab (blinded) | Myopathies | Phase 3 | NCT06455449 | JASMINE — A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING |